Detalhe da pesquisa
1.
Parameter-free continuous drift-diffusion models of amorphous organic semiconductors.
Phys Chem Chem Phys
; 17(35): 22778-83, 2015 Sep 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-26267617
2.
Integrating machine learning with pharmacokinetic models: Benefits of scientific machine learning in adding neural networks components to existing PK models.
CPT Pharmacometrics Syst Pharmacol
; 13(1): 41-53, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37843389
3.
Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
Clin Transl Sci
; 17(2): e13733, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38344875
4.
Artificial Intelligence for Quantitative Modeling in Drug Discovery and Development: An Innovation and Quality Consortium Perspective on Use Cases and Best Practices.
Clin Pharmacol Ther
; 115(4): 658-672, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37716910
5.
Upadacitinib Population Pharmacokinetics and Exposure-Response Relationships in Ulcerative Colitis Patients.
Clin Pharmacokinet
; 62(1): 101-112, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36571701
6.
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis.
Clin Pharmacokinet
; 62(4): 623-634, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36905528
7.
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum.
Parkinsonism Relat Disord
; 97: 68-72, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35339102
8.
Bridging Fixed Dose to Body Weight-based Regimen of Adalimumab in Paediatric Ulcerative Colitis Using a Pharmacometric Modelling Approach: Case Study with the Phase 3 ENVISION I Trial.
J Crohns Colitis
; 16(10): 1551-1561, 2022 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35526272
9.
Exposure-Response Model With Time-Varying Predictors to Estimate the Effects of Veliparib in Combination With Carboplatin/Paclitaxel and as Monotherapy: Veliparib Phase 3 Study in BRCA-Mutated Advanced Breast Cancer (BROCADE3) Trial.
J Clin Pharmacol
; 62(10): 1236-1246, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403245
10.
Validation of a quantitative systems pharmacology model of calcium homeostasis using elagolix Phase 3 clinical trial data in women with endometriosis.
Clin Transl Sci
; 14(4): 1611-1619, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963686
11.
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
J Clin Pharmacol
; 61(9): 1195-1205, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33894017
12.
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
J Clin Pharmacol
; 60(4): 528-539, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31701537
13.
Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients.
Cancer Chemother Pharmacol
; 84(5): 977-986, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31468137
14.
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
J Clin Pharmacol
; 59(9): 1225-1235, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30990907
15.
Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study.
Cancer Chemother Pharmacol
; 78(5): 1003-1011, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27709282